RxDoctor Payments Data

Mohamedlatif Saiyad, MD

Psychiatry · Marietta, OHNPI 1619233061

Payments from drug & device makers

$5,947in general payments, 2019–2025

Across 326 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$643
  • Takeda Pharmaceuticals U.S.A., Inc.$611
  • Alkermes, Inc.$440
  • Axsome Therapeutics, Inc.$344
  • Idorsia Pharmaceuticals US Inc$330
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$5,90999%
  • Education$381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,947 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$83,180
Medicare patients
242
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl163$252,456
Austedo XrDeutetrabenazine12$181,209
RexultiBrexpiprazole108$170,281
IngrezzaValbenazine Tosylate15$123,298
CaplytaLumateperone Tosylate30$47,784
TrintellixVortioxetine Hydrobromide70$42,873
Aripiprazole327$31,922
BelsomraSuvorexant45$20,334
QuviviqDaridorexant Hcl21$10,274
Vilazodone Hcl107$9,788
FetzimaLevomilnacipran Hcl12$8,609
QelbreeViloxazine Hcl13$8,389
Buspirone Hcl564$6,455
Quetiapine Fumarate286$5,852
Venlafaxine Hcl ErVenlafaxine Hcl171$4,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$2,074$261,065175 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$59$181,20912 claims
Otsuka America Pharmaceutical, Inc.Rexulti$643$170,281108 claims
Neurocrine Biosciences, Inc.Ingrezza$129$123,29815 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$264$47,78430 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$611$42,87370 claims
Idorsia Pharmaceuticals US IncQuviviq$330$10,27421 claims
Supernus Pharmaceuticals, Inc.Qelbree$18$8,38913 claims
Almatica Pharma LLCSertraline Hcl$23$2,488389 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Marietta

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →